Company Profile for Urologix, Inc.Business Editors --(BUSINESS WIRE) Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive invasive /in·va·sive/ (-siv) 1. having the quality of invasiveness. 2. involving puncture of the skin or insertion of an instrument or foreign material into the body; said of diagnostic techniques. medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia benign prostatic hyperplasia n. Abbr. BPH A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. (BPH BPH abbr. benign prostatic hyperplasia BPH Benign prostatic hypertrophy, a very common noncancerous cause of prostatic enlargement in older men. ), a condition that affects more than 23 million men worldwide. Urologix markets its products under the Targis Targis™ T3® system Urology A microwave, catheter-based system for nonsurgical treatment of BPH. See Benign prostatic hypertrophy. (TM) and Prostatron Prostatron® Urology A device for treating BPH using microwave heat without injuring adjacent healthy tissue with TUMT®–transurethral microwave thermotherapy. See Benign prostatic hypertrophy. (R) names. Both systems utilize Cooled ThermoTherapy ther·mo·ther·a·py n. Medical therapy involving the application of heat. thermotherapy (TM) -- targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort -- and provide safe, effective, lasting relief of the symptoms of BPH.
Company: Urologix, Inc.
Headquarters Address: 14405 21st Avenue North
Minneapolis, Minnesota 55447
Main Telephone: 763-475-1400
Website: www.urologix.com
Ticker: ULGX(NASDAQ)
Type of Organization: Public
Industry: Health: Medical Devices
Key Executives: Chairman & CEO: Fred B. Parks
VP, Finance & Controller: Todd E. Paulson
VP, Bus. Dev. & Strategic Planning: Kirsten
Doerfert
Investor Relations
Contact: Todd E. Paulson
Phone: 763-475-7683
Email: tpaulson@urologix.com
Investor Relations
Contact: Kirsten Doerfert
Phone: 763-475-7645
Email: kdoerfert@urologix.com
Investor Relations
Contact: Carolyn Nelson
Phone: 763-475-7664
Email: cnelson@urologix.com
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion